|
1
|
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
|
J Clin Oncol
|
2008
|
3.71
|
|
2
|
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.
|
Nat Med
|
2011
|
2.49
|
|
3
|
Influence of sex on the survival of patients with esophageal cancer.
|
J Clin Oncol
|
2012
|
2.29
|
|
4
|
Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.
|
Int J Cancer
|
2011
|
2.01
|
|
5
|
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
|
Clin Cancer Res
|
2008
|
1.53
|
|
6
|
Gender disparities in metastatic colorectal cancer survival.
|
Clin Cancer Res
|
2009
|
1.43
|
|
7
|
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
|
Clin Cancer Res
|
2008
|
1.34
|
|
8
|
Generation of a concise gene panel for outcome prediction in urinary bladder cancer.
|
J Clin Oncol
|
2009
|
1.32
|
|
9
|
Common cancer stem cell gene variants predict colon cancer recurrence.
|
Clin Cancer Res
|
2011
|
1.30
|
|
10
|
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.
|
Pharmacogenomics
|
2007
|
1.23
|
|
11
|
Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.
|
Cancer Res
|
2008
|
1.19
|
|
12
|
The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
|
Mol Cancer Ther
|
2012
|
1.15
|
|
13
|
Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation.
|
Pharmacogenomics
|
2006
|
1.14
|
|
14
|
9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: therapeutic implications of 9-cis retinoic acid for secondary lymphedema.
|
Circulation
|
2012
|
1.11
|
|
15
|
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
|
Clin Colorectal Cancer
|
2005
|
1.09
|
|
16
|
Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China.
|
Carcinogenesis
|
2007
|
1.02
|
|
17
|
DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value.
|
Clin Lung Cancer
|
2006
|
1.01
|
|
18
|
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
|
Clin Cancer Res
|
2011
|
1.00
|
|
19
|
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
|
Anticancer Res
|
2010
|
1.00
|
|
20
|
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.
|
Pharmacogenet Genomics
|
2008
|
0.98
|
|
21
|
Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups.
|
Br J Haematol
|
2012
|
0.97
|
|
22
|
Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.
|
Clin Cancer Res
|
2010
|
0.97
|
|
23
|
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
|
Clin Cancer Res
|
2005
|
0.96
|
|
24
|
Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.
|
Mol Cancer Ther
|
2013
|
0.95
|
|
25
|
Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression.
|
Mol Cancer Ther
|
2004
|
0.95
|
|
26
|
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
|
J Clin Oncol
|
2009
|
0.94
|
|
27
|
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
|
Clin Cancer Res
|
2011
|
0.92
|
|
28
|
Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.
|
Int J Cancer
|
2011
|
0.92
|
|
29
|
Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer.
|
Pharmacogenet Genomics
|
2009
|
0.91
|
|
30
|
Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
|
Clin Cancer Res
|
2005
|
0.91
|
|
31
|
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
|
PLoS One
|
2013
|
0.90
|
|
32
|
Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus.
|
Ann Surg
|
2010
|
0.88
|
|
33
|
Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women.
|
Breast Cancer Res Treat
|
2002
|
0.88
|
|
34
|
A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
|
Cancer Chemother Pharmacol
|
2010
|
0.87
|
|
35
|
Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
|
Clin Cancer Res
|
2011
|
0.87
|
|
36
|
ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
|
Drug Metab Lett
|
2007
|
0.86
|
|
37
|
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.
|
Mol Cancer Ther
|
2013
|
0.85
|
|
38
|
Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation.
|
Pharmacogenet Genomics
|
2006
|
0.85
|
|
39
|
Outcome disparities among ethnic subgroups of Waldenström's macroglobulinemia: a population-based study.
|
Oncology
|
2014
|
0.84
|
|
40
|
Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus.
|
Arch Surg
|
2004
|
0.83
|
|
41
|
Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer.
|
Clin Colorectal Cancer
|
2006
|
0.81
|
|
42
|
Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
|
Pharmacogenomics
|
2011
|
0.81
|
|
43
|
Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.
|
Pharmacogenet Genomics
|
2014
|
0.80
|
|
44
|
Drug abuse prevention program development. Results among Latino and non-Latino white adolescents.
|
Eval Health Prof
|
2003
|
0.78
|
|
45
|
Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care.
|
Clin Colorectal Cancer
|
2013
|
0.78
|
|
46
|
Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer.
|
Pharmacogenet Genomics
|
2015
|
0.77
|
|
47
|
Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study.
|
J Hematol Oncol
|
2009
|
0.76
|
|
48
|
CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development.
|
Int J Cancer
|
2014
|
0.75
|
|
49
|
Reply to J. Zhang et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
50
|
Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.
|
Pharmacogenet Genomics
|
2014
|
0.75
|
|
51
|
Three-dimensional virtual model and animation of penile lengthening surgery.
|
J Plast Reconstr Aesthet Surg
|
2012
|
0.75
|
|
52
|
Postoperative hydrophallus after penile lengthening: an experimental and clinical study.
|
Plast Reconstr Surg
|
2007
|
0.75
|
|
53
|
Clinical application of scrotal flap on penis lengthening.
|
Saudi Med J
|
2009
|
0.75
|